e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
Helen White, Nicola Shaw, Sarah Denman, Kim Pollard, Sarah Wynne, Daniel Gavin Peckham
Source:
Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016
Journal Issue:
March
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Helen White, Nicola Shaw, Sarah Denman, Kim Pollard, Sarah Wynne, Daniel Gavin Peckham. Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis
Source: Eur Respir J 2011; 37: 1091-1095
Year: 2011
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Source: Eur Respir J 2002; 20: 122-126
Year: 2002
Recommended shielding against SARS-CoV-2 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Combination of inhaled corticosteroids and long acting beta two agonists improve lung clearance index (LCI) in preschoolers with cystic fibrosis
Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge
Year: 2011
Optimising inhaled mannitol for cystic fibrosis in an adult population
Source: Breathe 2015; 11:39-48
Year: 2015
Lung function parameters influence serum concentration after antibiotic inhalation in patients with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 537s
Year: 2001
RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006
The influence of dornase alfa on long-term lung function in cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 538s
Year: 2001
The effect of inhaled steroids on bronchial hyperreactivity, oxidative status, clinical and inflammatory paramerters in patients with cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007
Lung clearance index improves with treatment of an exacerbation in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002
Reduced uptake of inhaled carbon in airway macrophages from children with cystic fibrosis
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis
Source: Eur Respir J 2002; 19: 294-302
Year: 2002
The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD
Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019
Year: 2019
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Improving airway clearance in cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 169-187
Year: 2014
Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept